HOLXHIGH SIGNALRISK10-K

HOLX has entered into a definitive merger agreement to be acquired by Blackstone funds while experiencing significant financial deterioration with net income declining 28.3%.

The addition of merger-related risk language indicates HOLX is being acquired by private equity giant Blackstone, which typically signals management believes the stock is undervalued or faces execution challenges better addressed privately. The substantial decline in profitability concurrent with the merger announcement suggests operational headwinds that may have motivated the sale, creating uncertainty about deal completion and fair value for shareholders.

Comparing 2025-11-18 vs 2024-11-27View on EDGAR →
FINANCIAL ANALYSIS

HOLX experienced broad-based financial deterioration with net income falling 28.3% to $565.7M and operating income declining 19.1% to $714.3M, indicating margin compression beyond just revenue challenges. Operating cash flow dropped 17.7% to $1.1B, showing the earnings decline is translating to reduced cash generation. This comprehensive financial weakening across profitability and cash flow metrics suggests fundamental business challenges that likely contributed to management's decision to pursue a sale to Blackstone.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-28.3%
$789.5M$565.7M

Net income declined 28.3% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-19.1%
$882.6M$714.3M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Operating Cash Flow
Cash Flow
-17.7%
$1.3B$1.1B

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

LANGUAGE CHANGES
NEW — 2025-11-18
PRIOR — 2024-11-27
ADDED
As of November 13, 2025, 222,905,228 shares of the registrant s Common Stock, $0.01 par value, were outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 37 Item 7A.
These statements involve known and unknown risks, uncertainties and other factors which may cause our or our industry s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements including, but not limited to: the timing, receipt and terms and conditions of any required governmental and regulatory approvals of the proposed merger (the Merger ) pursuant to the definitive agreement we entered into to be acquired by funds managed by Blackstone Inc.
and international governmental, regulatory, fiscal, monetary and public health responses to such crises; risks related to our ability to protect our intellectual property rights; risks related to anticipated trends relating to our financial condition or results of operations, including the impact of interest rate and foreign currency exchange fluctuations; risks related to estimated asset and liability values; risks related to our compliance with covenants contained in our debt agreements; and risks related to our liquidity, capital resources and the adequacy thereof.
In addition, we offer bacterial vaginosis and candida vaginitis assays, or BV/CV, for the diagnosis of vaginitis, a common and complex ailment affecting millions of women a year.
+7 more — sign up free →
REMOVED
As of November 21, 2024, 226,941,217 shares of the registrant s Common Stock, $0.01 par value, were outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 35 Item 7A.
These statements involve known and unknown risks, uncertainties and other factors which may cause our or our industry s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
In addition, we offer bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis, a common and complex ailment affecting millions of women a year.
Our assay portfolio also includes diagnostic tests for a range of acute respiratory infections, including SARS-CoV-2, various strains of influenza and parainfluenza, and respiratory syncytial virus, as well as a test for the detection of Group B Streptococcus, or GBS, that are run on the Panther Fusion system, a field upgradeable instrument addition to the base Panther system.
+7 more — sign up free →
MORE RISK SIGNALS
CAPSHIGHCAPS underwent a major business expansion through acquisitions while experiencin...
2026-04-16
KALAHIGHKALA has undergone a dramatic business transformation with massive share dilutio...
2026-04-15
RAINHIGHRain Enhancement Technologies underwent a financial restatement revealing signif...
2026-04-15
POLAHIGHPOLA experienced severe financial deterioration with gross profit turning negati...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →